A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Brief description of study

?The primary purpose of the study is to determine the effectiveness and tolerability of the experimental drug I-MIBG or the experimental drug crizotinib for high risk neuroblastoma (NBL) patients when they are undergoing recommended therapy which include chemotherapy plus surgery, two back-to-back stem cell transplants, radiation therapy, and immunotherapy. Crizotinib is an experimental anticancer drug that has not been approved by the FDA for use in treating high-risk NBL. U.S Food and Drug Administration (FDA) is the health authority that gives approval for new medicines to be prescribed in the United States.

Clinical Study Identifier: s18-01777
ClinicalTrials.gov Identifier: NCT03126916
Principal Investigator: Chana Glasser.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.